Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
Next report date
Report period
Q1 2024
EPS estimate
−0.66MXN
Revenue estimate
2.48 BMXN
−11.92MXN
−1.49 BMXN
10.05 BMXN
126.18 M
About NeoGenomics, Inc.
Sector
Industry
CEO
Christopher Michael Smith
Website
Headquarters
Fort Myers
Employees (FY)
2.1 K
Founded
1998
FIGI
BBG00PPX0G26
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NEO is featured.
Frequently Asked Questions
The current price of NEO is 198.50 MXN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange NEOGENOMICS INC stocks are traded under the ticker NEO.
NEOGENOMICS INC is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
NEO stock is 0% volatile and has beta coefficient of 1.78. Check out the list of the most volatile stocks — is NEOGENOMICS INC there?
NEOGENOMICS INC revenue for the last quarter amounts to 2.65 B MXN despite the estimated figure of 2.47 B MXN. In the next quarter revenue is expected to reach 2.59 B MXN.
Yes, you can track NEOGENOMICS INC financials in yearly and quarterly reports right on TradingView.
NEO net income for the last quarter is −243.33 M MXN, while the quarter before that showed −322.75 M MXN of net income which accounts for 24.61% change. Track more NEOGENOMICS INC financial stats to get the full picture.
Today NEOGENOMICS INC has the market capitalization of 30.42 B, it has increased by 2.35% over the last week.
No, NEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEOGENOMICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 2.10 K employees. See our rating of the largest employees — is NEOGENOMICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEOGENOMICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEOGENOMICS INC stock shows the sell signal. See more of NEOGENOMICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NEOGENOMICS INC future price: according to them, NEO price has a max estimate of 500.37 MXN and a min estimate of 300.22 MXN. Read a more detailed NEOGENOMICS INC forecast: see what analysts think of NEOGENOMICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEOGENOMICS INC EBITDA is −329.80 M MXN, and current EBITDA margin is −4.07%. See more stats in NEOGENOMICS INC financial statements.